search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


The role of PVAT in vascular ageing in chronic kidney disease and type 2 diabetes.


- candidate number29611
- NTR NumberNTR7684
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR1-okt-2018
- Secondary IDs201500869 Research register UMCG
- Public TitleThe role of PVAT in vascular ageing in chronic kidney disease and type 2 diabetes.
- Scientific TitleThe role of PVAT in vascular ageing in chronic kidney disease and type 2 diabetes.
- ACRONYMVascular Ageing Study
- hypothesisPVAT plays an important role in driving vascular ageing manifested by medial smooth muscle cell (SMC) dedifferentiation into an osteogenic phenotype that induces intimal and/or medial calcification. I furthermore hypothesize that this process of vascular inflammation and calcification is most severe in patients with both chronic kidney disease and Type 2 diabetes (diabetic nephropathy).
- Healt Condition(s) or Problem(s) studiedChronic kidney disease, Diabetes Mellitus Type 2 (DM type II), Accelerated vascular ageing
- Inclusion criteriaKidney donors:
- Men and women
- Age above 17 years

Kidney recipients:
- Men and women
- Age above 17 years
- Kidney failure leading to transplantation
- Exclusion criteria- Inadequate spreaking of Dutch language
- Age below 18 years
- Incompetent
- mec approval receivedyes
- multicenter trialno
- randomisedno
- groupParallel
- TypeSingle arm
- Studytypeobservational
- planned startdate 1-jan-2018
- planned closingdate1-jan-2020
- Target number of participants0
- InterventionsNot applicable.
- Primary outcome• Characterization of the pro-inflammatory and pro-calcifying environment of PVAT as compared to subcutaneous fat (SAT)
• Identification of potential differences in inflammatory profile between PVAT obtained from ‘healthy’ and calcified arterial wall
• Assessment of the effects on SMC calcification, dedifferentiation and contractile function in vitro of PVAT (compared to SAT)
- Secondary outcome- Role of type 2 diabetes mellitus in PVAT dysfunction
- Differences between end-stage renal disease and pre-emptive renal transplant recipients in its role of PVAT dysfunction
- TimepointsT0: informed consent
T1: venapuncture 1 day before transplantation
- Trial web siteNot applicable
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIES M. Reijrink
- CONTACT for SCIENTIFIC QUERIES M. Reijrink
- Sponsor/Initiator University Medical Center Groningen (UMCG)
- Funding
(Source(s) of Monetary or Material Support)
Astellas
- PublicationsNone yet.
- Brief summaryChronic kidney disease (CKD) is associated with a strong increase in cardiovascular risk, which is a consequence of accelerated vascular ageing. This process is hallmarked by vascular remodeling, chronic low-grade inflammation, calcification, and increased vascular stiffness. Vascular ageing is more pronounced in CKD patients who are also suffering from diabetes. The majority of type 2 diabetes (T2D) patients are obese with visceral adipose tissue (VAT) playing a central role in causing insulin resistance and metabolic syndrome. VAT is distributed through the abdominal cavity and is present surrounding the abdominal organs and the vasculature, the latter also called perivascular adipose tissue (PVAT). PVAT may be protective at some sites but it may also promote vascular ageing at other vascular sites because of its pro-atherogenic effects. This deranged function of PVAT may serve as a link between accelerated vascular ageing in CKD and T2D. I hypothesize that CKD and/or T2D derange PVAT function results in aggravated vascular ageing including development of atherosclerosis and calcification. In the current proposal, I will assess the pro-atherogenic environment of PVAT in patients with CKD with or without T2D.
In this study we will assess the role of T2D and CKD (end stage renal disease and pre emptive) in PVAT dysfunction.
- Main changes (audit trail)
- RECORD1-okt-2018 - 2-jan-2019


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl